No Data
Key points of interest in the PTS on the 17th = Silver Life, Daiwa, DD Group, ETC.
▽ Silver Life <9262.T>, upwardly revised the standalone performance forecast for the second quarter cumulative for the fiscal year ending July 2025 (August 2024 - January 2025) ▽ Daiwa <5888.T>, same-store sales for January increased by 8.5% year-on-year ▽ DD Group <3073.T>, same-store sales for January increased by 7.4% year-on-year ▽ Terrapro <6627.T>, sales for January increased by 4.6% year-on-year ▽ Gakujo <2301.T>, announced a share buyback ▽ SREHD <2980.T>, Sell Stocks.
Toho's operating profit in the third quarter increased by 26.9% to 52.8 billion yen.
Toho <9602> announced that for the third quarter of the fiscal period ending February 2025, operating revenue increased by 15.3% year-on-year to 234.169 billion yen, and operating profit rose by 26.9% to 52.81 billion yen. The film exhibition business saw a decrease in both revenue and profit compared to the previous year, but the sales of character goods related to Toho's monster characters, centered around 'Godzilla,' significantly contributed to operating income. 【Positive evaluation】 <3266> FundクリG full year | <9837> Morito full year <4413> Board
Star seeds: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending 2025/2 [Japanese GAAP] (Consolidated)
Kasumigaseki Capital, Asahi Chemicals, Toho, Bunkyo HD (14th)
※ The above Calendar is merely a schedule and may be subject to change due to corporate circumstances. --------------------------------------- January 14 (Tuesday) <135A> VRAIN <1377> Sakata Seed <138A> Hikari Food Service <1401> mbs <1407> West HD <1418> Interlife <1419> Tama Home <1430> 1st Co.
December 27 [Today's Investment Strategy]
[Selected Stocks by Fisco] 【Material Stocks】 Kaken Pharmaceutical <4521> 4174 yen (12/26) Main products include the nail fungus treatment 'Klenafin' and the joint function improvement drug 'Alts'. The company announced the signing of a contract granting Johnson & Johnson exclusive rights for the development, manufacturing, and commercialization globally of the 'STAT6 Program', which is being developed as a next-generation oral treatment for type 2 inflammatory diseases (such as atopic dermatitis and asthma).
Focus on DeNA and Kaken Pharmaceutical, while Oisix and Sankyo Tateyama may be sluggish.
In the US stock market on the 26th, the Dow Jones Industrial Average rose by $28.77 to 43,325.80, the Nasdaq Composite Index fell by 10.77 points to 20,020.36, and the Chicago Nikkei 225 Futures were up by 210 yen compared to Osaka daytime at 39,700 yen. The exchange rate was 1 dollar = 158.00-10 yen. In today's Tokyo market, Kusuri no Aoki <3549> saw an increase in operating profit of 85.5%, expanding from 10.2% growth in the first quarter, and the performance of its gaming business for the fiscal year ending in March 2025 is expected to see an increase in both revenue and profit compared to the previous period.